These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22753741)

  • 21. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
    Fukushima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
    Tomoda M; Kawahara H; Watanabe K; Enomoto H; Akiba T; Yanaga K
    Anticancer Res; 2014 Jan; 34(1):191-4. PubMed ID: 24403461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
    Twelves C
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):23-6. PubMed ID: 12520636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Progress in chemotherapy for colorectal cancer].
    Sasaki T; Maeda Y
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2185-92. PubMed ID: 11142161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
    Moreno-Solórzano I; Ibeas-Rollan R; Monzó-Planella M; Moreno-Solórzano J; Martínez-Ródenas F; Pou-Sanchis E; Hernández-Borlan R; Navarro-Vigo M; Ortigosa-Rodríguez S; Gel-Moreno B
    Clin Colorectal Cancer; 2007 Sep; 6(9):634-40. PubMed ID: 17945035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
    Shields AF; Zalupski MM; Marshall JL; Meropol NJ
    Cancer; 2004 Feb; 100(3):531-7. PubMed ID: 14745869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma.
    Tachimori A; Yamada N; Amano R; Ohira M; Hirakawa K
    Anticancer Res; 2008; 28(2A):629-38. PubMed ID: 18507001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
    Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
    Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Lee J; Shin SJ; Chung IJ; Kim TW; Chun HG; Shin DB; Kim YH; Song HS; Han SW; Kim JG; Kim SY; Choi YJ; Chung HC
    Invest New Drugs; 2014 Jun; 32(3):561-8. PubMed ID: 24573743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts.
    Ooyama A; Oka T; Zhao HY; Yamamoto M; Akiyama S; Fukushima M
    Cancer Lett; 2008 Aug; 267(1):26-36. PubMed ID: 18420342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
    Fukushima M; Sakamoto K; Sakata M; Nakagawa F; Saito H; Sakata Y
    Oncol Rep; 2010 Nov; 24(5):1307-13. PubMed ID: 20878125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
    Porschen R; Arkenau HT; Kubicka S; Greil R; Seufferlein T; Freier W; Kretzschmar A; Graeven U; Grothey A; Hinke A; Schmiegel W; Schmoll HJ;
    J Clin Oncol; 2007 Sep; 25(27):4217-23. PubMed ID: 17548840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Capecitabine chemotherapy for metastatic colorectal cancer. Chemical structure, combinations and efficacy.
    Koukourakis G; Kouloulias V; Zacharias G; Koukourakis M
    J BUON; 2010; 15(4):652-9. PubMed ID: 21229625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
    Nukatsuka M; Saito H; Nakagawa F; Abe M; Uchida J; Shibata J; Matsuo K; Noguchi S; Kiniwa M
    Breast Cancer Res Treat; 2011 Jul; 128(2):381-90. PubMed ID: 20809360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor Efficacy of Combination Therapy Consisting of S-1, Leucovorin, and Oxaliplatin against Human Gastric Cancer Xenografts.
    Nagase H; Nakagawa F; Uchida J
    Chemotherapy; 2018; 63(1):46-52. PubMed ID: 29393100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.
    Kase S; Kubota T; Watanabe M; Furukawa T; Tanino H; Ishibiki K; Teramoto T; Kitajima M
    Anticancer Res; 1993; 13(2):369-73. PubMed ID: 8517649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.
    Kolinsky K; Zhang YE; Dugan U; Heimbrook D; Packman K; Higgins B
    Anticancer Res; 2009 Jan; 29(1):91-8. PubMed ID: 19331137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer.
    Lin PC; Chen WS; Chao TC; Yang SH; Tiu CM; Liu JH
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):351-6. PubMed ID: 17111120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.